# OnCo record pucotenlimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pucotenlimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pucotenlimab" ;
  schema:name "Pucotenlimab"@en ;
  schema:description "Pucotenlimab is Lepu Biopharma's PD-1 antibody, approved in China in 2022 for mismatch-repair-deficient solid tumours and for melanoma, and in a phase 3 trial in colorectal cancer."@en ;
  schema:url <https://onco.cc/drugs/pucotenlimab/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=HX008> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Anti-PD-1 monoclonal antibody, intravenous" ;
  onco:approval "CN 2022: Previously treated MSI-high or dMMR advanced solid tumours; unresectable or metastatic melanoma after prior therapy" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/lepu-biopharma/> ;
  onco:trials <https://onco.cc/trials/nct05652894/>, <https://onco.cc/trials/nct06976190/>, <https://onco.cc/trials/nct07479485/>, <https://onco.cc/trials/nct07586124/> .